LINK Medical AS og Melanor inngår samarbeidsavtale
LINK Medial AS og Melanor har inngått samarbeidsavtale som gir medlemmer tilgang til nødvendig kompetanse og rådgiving på gunstige vilkår i prosessen mot registering av medisinsk utstyr.
Categories: Clinical-study
LINK Medical contracted by Hemanext to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System
Hemanext, inc. appoints LINK Medical Research to run a study to assess the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System. The study will include patients that receive transfusions of hypoxic RBC units processed with Hemanext ONE, with the purpose of evaluating the safety and efficacy of hypoxic red blood cells processed with the Hemanext ONE system.
LIPIGON CHOOSES LINK MEDICAL AS THEIR CRO
Lipigon Pharmaceuticals AB have chosen LINK Medical, a Nordic contract research organization (CRO) for the planning and design of their clinical phase II study with Lipisense. The study aims to study safety and treatment effects in patients with severely elevated levels of the blood fat triglyceride.
Positive Results for AlzeCure’s Phase IIa clinical study in neuropathic pain with the non-opioid ACD440
LINK Medical, and AlzeCure® Pharma AB (publ) (FN STO: ALZCUR) announce the positive data results from the Phase IIa clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain
Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe
Pharm Assist is now part of LINK Medical, making the Regulatory team one of the largest and unique in Northern Europe
The patient recruitment milestone has been reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440
LINK Medical, the Northern European clinical research organization (CRO), and AlzeCureÒ Pharma AB (publ) (FN STO: ALZCUR), announced today that the last patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440.
New CEO at LINK Medical, the Northern European CRO
The LINK Medical Board is pleased to announce the appointment of Sissel Lønning Andresen as the new CEO of LINK Medical one of the leading Northern European CROs. Sissel will assume the company's CEO position as of January 1st, 2023.
Strategic Advice Provides a Shortcut to Success
Many biotech companies have a strong research base but lack the knowledge and experience needed to bring their products closer to the market. LINK Medical Research can help to map the strategic pathway.
Another milestone reached for AlzeCure's Phase II clinical trial in neuropathic pain with non-opioid ACD440
The first patient has been enrolled in the phase II clinical trial for neuropathic pain treated with the non-opioid ACD440. The Phase II clinical trial is a double-blind, placebo-controlled, randomized cross-over study evaluating the efficacy, safety, and pharmacokinetics of AlzeCure's leading drug candidate in pain, ACD440. Results from the study are expected in mid-2023.
LINK Medical, the Northern European CRO has raised capital to fund further growth
To enable further growth and provide new competencies to the company, Ola Gudmundsen has decided to invite Serendipity as co-owners and long-term investors in LINK Medical.
Closing the gap between developers and users results in a unique eTMF solution
Viedoc eClinical solutions are originally developed in close collaboration between users and experts in digital technology starting two decades ago. This process has continued in the eTMF development where Viedoc brought eTMF experts, closer to the development team.
Full-service CRO LINK Medical and Viedoc™ sign a new partnership agreement
LINK Medical and Viedoc announced today a new Partnership Program between the two companies. The Partnership Program established by Viedoc is designed to improve trial efficiency for LINK Medical and its clients. It allows for continuous exchange of experience, needs, and ideas, as well as testing of new features.
Key considerations to be aware of with Clinical Trial Regulation (CTR) EU No 536/2014
The Clinical Trial Regulation (Regulation (EU) No 536/2014) will replace the Clinical Trials Directive 2001/20/EC and aims to ensure a higher level of harmonization of the rules for authorizing and conducting clinical trials throughout the EU thus making it more attractive to conduct clinical trials in the EU. The new regulation goes into effect on the 31st of January 2022.
LINK Medical strengthens its stand-out Real World Evidence (RWE) department with a uniquely qualified expert, Maria Hortlund
LINK Medical strengthens its stand-out Real World Evidence (RWE) department with a uniquely qualified expert, Maria Hortlund
LINK Medical expands its regulatory services team, strengthening its IMPD & CMC capabilities
LINK Medical, the Northern European clinical research organization (CRO), recently announced the expansion of its regulatory team with the recent appointment of new regulatory directors in Norway, Sweden and Denmark.
LINK Medical Research appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer
LINK Medical Research has been appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer. This is significant news as bladder cancer is one of the most aggressive cancers; 50-70% of tumours recur and 10-20% become metastatic. Current treatments of metastatic bladder cancer require frequent, long hospital visits, have limited efficacy a
